| Sponsor |
Protocol Code |
Trial Name |
Principal Investigator |
Phase |
Therapeutic Area |
Diseases and Conditions |
| ROCHE |
GO42909 |
Phase III Randomized, Open-Label,Multicenter Study Evaluating Efficacy And Safety Of Mosunetuzumab In Combination With Lenalidomide In Comparison To Rituximab In Combination With Lenalidomide In Patients With Follicular Lymphoma After At Least One Line Of Systemic Therapy |
MELTEM AKAY (Prof.Dr.) |
Phase 3 |
Hematology |
Lymphoma |
| AbbVie |
M20-429 |
A Single Arm, Open-Label, Phase lb Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms |
MEHMET FATİH ERBEY (Prof.Dr.) |
Phase 1b |
Hematology |
Lymphoma |
| Johnson and Johnson |
88998377LYM1001 |
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants with Relapsed/Refractory B-cell NHL |
SİNEM CİVRİZ BOZDAĞ ( Prof.Dr.) |
Phase 1 |
Hematology |
Lymphoma |
| Cynata Therapeutics Limited |
CYP-GvHD-P2-01_HAB91733 |
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease |
SİNEM CİVRİZ BOZDAĞ ( Prof.Dr.) |
Phase 2 |
Hematology |
Acute Graft-versus-Host |
| GSK |
218670 |
A Phase 1/2 open-label, multicentre, dose escalation and expansion study to investigate the safety, tolerability, and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma. |
SİNEM CİVRİZ BOZDAĞ ( Prof.Dr.) |
Phase 1/2 |
Hematology |
Multiple Myeloma |
| Johnson and Johnson |
75276617AML3001 |
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy |
BERRİN BALIK (Dr.) |
Phase 3 |
Hematology |
Acute Myeloid Leukemia (AML) |
| Johnson and Johnson |
95566692LYM1001 |
A Phase 1, First-in-Human Study of a novel CD79bxCD20xCD3 Trispecific Antibody in B-cell Non-Hodgkin Lymphoid Malignancies (NHLs) |
SİNEM CİVRİZ BOZDAĞ ( Prof.Dr.) |
Phase 1 |
Hematology |
Lymphoma |